Advertisement

Index by author

September 01, 1996; Volume 50,Issue 3

A

  1. Alvaro, J D

    1. Morphine down-regulates melanocortin-4 receptor expression in brain regions that mediate opiate addiction.
      J D Alvaro, J B Tatro, J M Quillan, M Fogliano, M Eisenhard, M R Lerner, E J Nestler and R S Duman
      Molecular Pharmacology September 1996, 50 (3) 583-591;

  2. Animati, F

    1. Biochemical and pharmacological activity of novel 8-fluoroanthracyclines: influence of stereochemistry and conformation.
      F Animati, F Arcamone, M Bigioni, G Capranico, C Caserini, M De Cesare, P Lombardi, G Pratesi, C Salvatore, R Supino and F Zunino
      Molecular Pharmacology September 1996, 50 (3) 603-609;

  3. Arai, H

    1. Angiotensin II type 1 receptor signals through Raf-1 by a protein kinase C-dependent, Ras-independent mechanism.
      H Arai and J A Escobedo
      Molecular Pharmacology September 1996, 50 (3) 522-528;

  4. Arcamone, F

    1. Biochemical and pharmacological activity of novel 8-fluoroanthracyclines: influence of stereochemistry and conformation.
      F Animati, F Arcamone, M Bigioni, G Capranico, C Caserini, M De Cesare, P Lombardi, G Pratesi, C Salvatore, R Supino and F Zunino
      Molecular Pharmacology September 1996, 50 (3) 603-609;

B

  1. Bamberger, U

    1. BIBW22 BS, potent multidrug resistance-reversing agent, binds directly to P-glycoprotein and accumulates in drug-resistant cells.
      Z Liu, F Lheureux, J F Pouliot, A Heckel, U Bamberger and E Georges
      Molecular Pharmacology September 1996, 50 (3) 482-492;

  2. Barak, D

    1. Interactions of oxime reactivators with diethylphosphoryl adducts of human acetylcholinesterase and its mutant derivatives.
      H Grosfeld, D Barak, A Ordentlich, B Velan and A Shafferman
      Molecular Pharmacology September 1996, 50 (3) 639-649;

  3. Barber, R

    1. Repetitive endocytosis and recycling of the beta 2-adrenergic receptor during agonist-induced steady state redistribution.
      K J Morrison, R H Moore, N D Carsrud, J Trial, E E Millman, M Tuvim, R B Clark, R Barber, B F Dickey and B J Knoll
      Molecular Pharmacology September 1996, 50 (3) 692-699;

  4. Berger, A

    1. Structural requirements of sphingosylphosphocholine and sphingosine-1-phosphate for stimulation of activator protein-1 activity.
      A Berger, R Bittman, R R Schmidt and S Spiegel
      Molecular Pharmacology September 1996, 50 (3) 451-457;

  5. Bigioni, M

    1. Biochemical and pharmacological activity of novel 8-fluoroanthracyclines: influence of stereochemistry and conformation.
      F Animati, F Arcamone, M Bigioni, G Capranico, C Caserini, M De Cesare, P Lombardi, G Pratesi, C Salvatore, R Supino and F Zunino
      Molecular Pharmacology September 1996, 50 (3) 603-609;

  6. Birnbaumer, M

    1. A fully active nonglycosylated V2 vasopressin receptor.
      G Innamorati, H Sadeghi and M Birnbaumer
      Molecular Pharmacology September 1996, 50 (3) 467-473;

  7. Bittman, R

    1. Structural requirements of sphingosylphosphocholine and sphingosine-1-phosphate for stimulation of activator protein-1 activity.
      A Berger, R Bittman, R R Schmidt and S Spiegel
      Molecular Pharmacology September 1996, 50 (3) 451-457;
    2. N-palmitoyl-serine and N-palmitoyl-tyrosine phosphoric acids are selective competitive antagonists of the lysophosphatidic acid receptors.
      K Liliom, R Bittman, B Swords and G Tigyi
      Molecular Pharmacology September 1996, 50 (3) 616-623;

  8. Bouvier, M

    1. Agonist-induced modulation of inverse agonist efficacy at the beta 2-adrenergic receptor.
      P Chidiac, S Nouet and M Bouvier
      Molecular Pharmacology September 1996, 50 (3) 662-669;

  9. Bradford, B U

    1. Detection of alpha-hydroxyethyl free radical adducts in the pancreas after chronic exposure to alcohol in the rat.
      Y Iimuro, B U Bradford, W Gao, M Kadiiska, R P Mason, B Stefanovic, D A Brenner and R G Thurman
      Molecular Pharmacology September 1996, 50 (3) 656-661;

  10. Brenner, D A

    1. Detection of alpha-hydroxyethyl free radical adducts in the pancreas after chronic exposure to alcohol in the rat.
      Y Iimuro, B U Bradford, W Gao, M Kadiiska, R P Mason, B Stefanovic, D A Brenner and R G Thurman
      Molecular Pharmacology September 1996, 50 (3) 656-661;

C

  1. Cai, J J

    1. Cyclic AMP-dependent phosphodiesterase isozyme-specific potentiation by protein kinase C in hypertrophic cardiomyopathic hamster hearts.
      H Yu, J J Cai and H C Lee
      Molecular Pharmacology September 1996, 50 (3) 549-555;

  2. Capranico, G

    1. Biochemical and pharmacological activity of novel 8-fluoroanthracyclines: influence of stereochemistry and conformation.
      F Animati, F Arcamone, M Bigioni, G Capranico, C Caserini, M De Cesare, P Lombardi, G Pratesi, C Salvatore, R Supino and F Zunino
      Molecular Pharmacology September 1996, 50 (3) 603-609;

  3. Cardenas, M E

    1. Calcineurin mutants render T lymphocytes resistant to cyclosporin A.
      D Zhu, M E Cardenas and J Heitman
      Molecular Pharmacology September 1996, 50 (3) 506-511;

  4. Carsrud, N D

    1. Repetitive endocytosis and recycling of the beta 2-adrenergic receptor during agonist-induced steady state redistribution.
      K J Morrison, R H Moore, N D Carsrud, J Trial, E E Millman, M Tuvim, R B Clark, R Barber, B F Dickey and B J Knoll
      Molecular Pharmacology September 1996, 50 (3) 692-699;

  5. Caserini, C

    1. Biochemical and pharmacological activity of novel 8-fluoroanthracyclines: influence of stereochemistry and conformation.
      F Animati, F Arcamone, M Bigioni, G Capranico, C Caserini, M De Cesare, P Lombardi, G Pratesi, C Salvatore, R Supino and F Zunino
      Molecular Pharmacology September 1996, 50 (3) 603-609;

  6. Chang, K J

    1. The stimulatory effect of opioids on mitogen-activated protein kinase in Chinese hamster ovary cells transfected to express mu-opioid receptors.
      L Y Li and K J Chang
      Molecular Pharmacology September 1996, 50 (3) 599-602;

  7. Chidiac, P

    1. Agonist-induced modulation of inverse agonist efficacy at the beta 2-adrenergic receptor.
      P Chidiac, S Nouet and M Bouvier
      Molecular Pharmacology September 1996, 50 (3) 662-669;

  8. Chieng, B

    1. The mu-opioid receptor antagonist D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH2 (CTOP) [but not D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 (CTAP)] produces a nonopioid receptor-mediated increase in K+ conductance of rat locus ceruleus neurons.
      B Chieng, M Connor and M J Christie
      Molecular Pharmacology September 1996, 50 (3) 650-655;

  9. Christie, M J

    1. The mu-opioid receptor antagonist D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH2 (CTOP) [but not D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 (CTAP)] produces a nonopioid receptor-mediated increase in K+ conductance of rat locus ceruleus neurons.
      B Chieng, M Connor and M J Christie
      Molecular Pharmacology September 1996, 50 (3) 650-655;

  10. Clark, R B

    1. Repetitive endocytosis and recycling of the beta 2-adrenergic receptor during agonist-induced steady state redistribution.
      K J Morrison, R H Moore, N D Carsrud, J Trial, E E Millman, M Tuvim, R B Clark, R Barber, B F Dickey and B J Knoll
      Molecular Pharmacology September 1996, 50 (3) 692-699;

  11. Connor, M

    1. The mu-opioid receptor antagonist D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH2 (CTOP) [but not D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 (CTAP)] produces a nonopioid receptor-mediated increase in K+ conductance of rat locus ceruleus neurons.
      B Chieng, M Connor and M J Christie
      Molecular Pharmacology September 1996, 50 (3) 650-655;

D

  1. Day, R O

    1. D-penicillamine causes free radical-dependent inactivation of activator protein-1 DNA binding.
      M L Handel, C K Watts, S Sivertsen, R O Day and R L Sutherland
      Molecular Pharmacology September 1996, 50 (3) 501-505;

  2. De Cesare, M

    1. Biochemical and pharmacological activity of novel 8-fluoroanthracyclines: influence of stereochemistry and conformation.
      F Animati, F Arcamone, M Bigioni, G Capranico, C Caserini, M De Cesare, P Lombardi, G Pratesi, C Salvatore, R Supino and F Zunino
      Molecular Pharmacology September 1996, 50 (3) 603-609;

  3. De Souza, E B

    1. 125I-Tyro-sauvagine: a novel high affinity radioligand for the pharmacological and biochemical study of human corticotropin-releasing factor 2 alpha receptors.
      D E Grigoriadis, X J Liu, J Vaughn, S F Palmer, C D True, W W Vale, N Ling and E B De Souza
      Molecular Pharmacology September 1996, 50 (3) 679-686;

  4. Dickey, B F

    1. Repetitive endocytosis and recycling of the beta 2-adrenergic receptor during agonist-induced steady state redistribution.
      K J Morrison, R H Moore, N D Carsrud, J Trial, E E Millman, M Tuvim, R B Clark, R Barber, B F Dickey and B J Knoll
      Molecular Pharmacology September 1996, 50 (3) 692-699;

  5. Diehl, N L

    1. Direct evidence for functional coupling of the vasoactive intestinal peptide receptor to Gi3 in native lung membranes.
      N L Diehl, J C Kermode and S M Shreeve
      Molecular Pharmacology September 1996, 50 (3) 624-630;

  6. Duman, R S

    1. Morphine down-regulates melanocortin-4 receptor expression in brain regions that mediate opiate addiction.
      J D Alvaro, J B Tatro, J M Quillan, M Fogliano, M Eisenhard, M R Lerner, E J Nestler and R S Duman
      Molecular Pharmacology September 1996, 50 (3) 583-591;

E

  1. Eisenhard, M

    1. Morphine down-regulates melanocortin-4 receptor expression in brain regions that mediate opiate addiction.
      J D Alvaro, J B Tatro, J M Quillan, M Fogliano, M Eisenhard, M R Lerner, E J Nestler and R S Duman
      Molecular Pharmacology September 1996, 50 (3) 583-591;

  2. Eisfelder, B

    1. Constitutive activation of a phosphoinositidase C-linked G protein in murine fibroblasts decreases agonist-stimulated Ca2+ mobilization.
      L A Lobaugh, B Eisfelder, K Gibson, G L Johnson and J W Putney
      Molecular Pharmacology September 1996, 50 (3) 493-500;

  3. Eliasson, E

    1. Cytochrome P450 2E1 is a cell surface autoantigen in halothane hepatitis.
      E Eliasson and J G Kenna
      Molecular Pharmacology September 1996, 50 (3) 573-582;

  4. Escobedo, J A

    1. Angiotensin II type 1 receptor signals through Raf-1 by a protein kinase C-dependent, Ras-independent mechanism.
      H Arai and J A Escobedo
      Molecular Pharmacology September 1996, 50 (3) 522-528;

F

  1. Fernandez-Salguero, P

    1. Piperonyl butoxide and acenaphthylene induce cytochrome P450 1A2 and 1B1 mRNA in aromatic hydrocarbon-responsive receptor knock-out mouse liver.
      D Y Ryu, P E Levi, P Fernandez-Salguero, F J Gonzalez and E Hodgson
      Molecular Pharmacology September 1996, 50 (3) 443-446;

  2. Fogliano, M

    1. Morphine down-regulates melanocortin-4 receptor expression in brain regions that mediate opiate addiction.
      J D Alvaro, J B Tatro, J M Quillan, M Fogliano, M Eisenhard, M R Lerner, E J Nestler and R S Duman
      Molecular Pharmacology September 1996, 50 (3) 583-591;

  3. Fukuhara, M

    1. Okadaic acid potentiates 3-methylcholanthrene-induced CYP2A8 gene expression in primary cultures of Syrian hamster hepatocytes: possible involvement of activator protein-1.
      M Tohkin, K Kurose and M Fukuhara
      Molecular Pharmacology September 1996, 50 (3) 556-564;

G

  1. Gao, W

    1. Detection of alpha-hydroxyethyl free radical adducts in the pancreas after chronic exposure to alcohol in the rat.
      Y Iimuro, B U Bradford, W Gao, M Kadiiska, R P Mason, B Stefanovic, D A Brenner and R G Thurman
      Molecular Pharmacology September 1996, 50 (3) 656-661;

  2. Georges, E

    1. BIBW22 BS, potent multidrug resistance-reversing agent, binds directly to P-glycoprotein and accumulates in drug-resistant cells.
      Z Liu, F Lheureux, J F Pouliot, A Heckel, U Bamberger and E Georges
      Molecular Pharmacology September 1996, 50 (3) 482-492;

  3. Gibson, K

    1. Constitutive activation of a phosphoinositidase C-linked G protein in murine fibroblasts decreases agonist-stimulated Ca2+ mobilization.
      L A Lobaugh, B Eisfelder, K Gibson, G L Johnson and J W Putney
      Molecular Pharmacology September 1996, 50 (3) 493-500;

  4. Gonzalez, F J

    1. Piperonyl butoxide and acenaphthylene induce cytochrome P450 1A2 and 1B1 mRNA in aromatic hydrocarbon-responsive receptor knock-out mouse liver.
      D Y Ryu, P E Levi, P Fernandez-Salguero, F J Gonzalez and E Hodgson
      Molecular Pharmacology September 1996, 50 (3) 443-446;

  5. Gribkoff, V K

    1. Use of subunit-specific antisense oligodeoxynucleotides to define developmental changes in the properties of N-methyl-D-aspartate receptors.
      J Zhong, V K Gribkoff and P B Molinoff
      Molecular Pharmacology September 1996, 50 (3) 631-638;

  6. Grigoriadis, D E

    1. 125I-Tyro-sauvagine: a novel high affinity radioligand for the pharmacological and biochemical study of human corticotropin-releasing factor 2 alpha receptors.
      D E Grigoriadis, X J Liu, J Vaughn, S F Palmer, C D True, W W Vale, N Ling and E B De Souza
      Molecular Pharmacology September 1996, 50 (3) 679-686;

  7. Grosfeld, H

    1. Interactions of oxime reactivators with diethylphosphoryl adducts of human acetylcholinesterase and its mutant derivatives.
      H Grosfeld, D Barak, A Ordentlich, B Velan and A Shafferman
      Molecular Pharmacology September 1996, 50 (3) 639-649;

  8. Gustafsson, J A

    1. Trans-activation by the human aryl hydrocarbon receptor and aryl hydrocarbon receptor nuclear translocator proteins: direct interactions with basal transcription factors.
      J C Rowlands, I J McEwan and J A Gustafsson
      Molecular Pharmacology September 1996, 50 (3) 538-548;

H

  1. Handel, M L

    1. D-penicillamine causes free radical-dependent inactivation of activator protein-1 DNA binding.
      M L Handel, C K Watts, S Sivertsen, R O Day and R L Sutherland
      Molecular Pharmacology September 1996, 50 (3) 501-505;

  2. Heckel, A

    1. BIBW22 BS, potent multidrug resistance-reversing agent, binds directly to P-glycoprotein and accumulates in drug-resistant cells.
      Z Liu, F Lheureux, J F Pouliot, A Heckel, U Bamberger and E Georges
      Molecular Pharmacology September 1996, 50 (3) 482-492;

  3. Heitman, J

    1. Calcineurin mutants render T lymphocytes resistant to cyclosporin A.
      D Zhu, M E Cardenas and J Heitman
      Molecular Pharmacology September 1996, 50 (3) 506-511;

  4. Hodgson, E

    1. Piperonyl butoxide and acenaphthylene induce cytochrome P450 1A2 and 1B1 mRNA in aromatic hydrocarbon-responsive receptor knock-out mouse liver.
      D Y Ryu, P E Levi, P Fernandez-Salguero, F J Gonzalez and E Hodgson
      Molecular Pharmacology September 1996, 50 (3) 443-446;

  5. Horisberger, J D

    1. Mercury binding site on Na+/K(+)-ATPase: a cysteine in the first transmembrane segment.
      X Wang and J D Horisberger
      Molecular Pharmacology September 1996, 50 (3) 687-691;

  6. Hwang, S M

    1. Studies on alpha v beta 3/ligand interactions using a [3H]SK&F-107260 binding assay.
      A Wong, S M Hwang, P McDevitt, D McNulty, J M Stadel and K Johanson
      Molecular Pharmacology September 1996, 50 (3) 529-537;

I

  1. Iimuro, Y

    1. Detection of alpha-hydroxyethyl free radical adducts in the pancreas after chronic exposure to alcohol in the rat.
      Y Iimuro, B U Bradford, W Gao, M Kadiiska, R P Mason, B Stefanovic, D A Brenner and R G Thurman
      Molecular Pharmacology September 1996, 50 (3) 656-661;

  2. Innamorati, G

    1. A fully active nonglycosylated V2 vasopressin receptor.
      G Innamorati, H Sadeghi and M Birnbaumer
      Molecular Pharmacology September 1996, 50 (3) 467-473;

J

  1. Jacobson, K A

    1. Hydrophilic side chains in the third and seventh transmembrane helical domains of human A2A adenosine receptors are required for ligand recognition.
      Q Jiang, A M Van Rhee, J Kim, S Yehle, J Wess and K A Jacobson
      Molecular Pharmacology September 1996, 50 (3) 512-521;

  2. Jeong, J K

    1. Quinone thioether-mediated DNA damage, growth arrest, and gadd153 expression in renal proximal tubular epithelial cells.
      J K Jeong, J L Stevens, S S Lau and T J Monks
      Molecular Pharmacology September 1996, 50 (3) 592-598;

  3. Jiang, Q

    1. Hydrophilic side chains in the third and seventh transmembrane helical domains of human A2A adenosine receptors are required for ligand recognition.
      Q Jiang, A M Van Rhee, J Kim, S Yehle, J Wess and K A Jacobson
      Molecular Pharmacology September 1996, 50 (3) 512-521;

  4. Johanson, K

    1. Studies on alpha v beta 3/ligand interactions using a [3H]SK&F-107260 binding assay.
      A Wong, S M Hwang, P McDevitt, D McNulty, J M Stadel and K Johanson
      Molecular Pharmacology September 1996, 50 (3) 529-537;

  5. Johnson, G L

    1. Constitutive activation of a phosphoinositidase C-linked G protein in murine fibroblasts decreases agonist-stimulated Ca2+ mobilization.
      L A Lobaugh, B Eisfelder, K Gibson, G L Johnson and J W Putney
      Molecular Pharmacology September 1996, 50 (3) 493-500;

  6. Jover, R

    1. Role of heme in cytochrome P450 transcription and function in mice treated with lead acetate.
      R Jover, R L Lindberg and U A Meyer
      Molecular Pharmacology September 1996, 50 (3) 474-481;

K

  1. Kadiiska, M

    1. Detection of alpha-hydroxyethyl free radical adducts in the pancreas after chronic exposure to alcohol in the rat.
      Y Iimuro, B U Bradford, W Gao, M Kadiiska, R P Mason, B Stefanovic, D A Brenner and R G Thurman
      Molecular Pharmacology September 1996, 50 (3) 656-661;

  2. Kapur, J

    1. Pharmacological properties of gamma-aminobutyric acidA receptors from acutely dissociated rat dentate granule cells.
      J Kapur and R L Macdonald
      Molecular Pharmacology September 1996, 50 (3) 458-466;

  3. Kenna, J G

    1. Cytochrome P450 2E1 is a cell surface autoantigen in halothane hepatitis.
      E Eliasson and J G Kenna
      Molecular Pharmacology September 1996, 50 (3) 573-582;

  4. Kermode, J C

    1. Direct evidence for functional coupling of the vasoactive intestinal peptide receptor to Gi3 in native lung membranes.
      N L Diehl, J C Kermode and S M Shreeve
      Molecular Pharmacology September 1996, 50 (3) 624-630;

  5. Kieffer, B

    1. Functional selectivity of orphanin FQ for its receptor coexpressed with potassium channel subunits in Xenopus laevis oocytes.
      H Matthes, E P Seward, B Kieffer and R A North
      Molecular Pharmacology September 1996, 50 (3) 447-450;

  6. Kim, J

    1. Hydrophilic side chains in the third and seventh transmembrane helical domains of human A2A adenosine receptors are required for ligand recognition.
      Q Jiang, A M Van Rhee, J Kim, S Yehle, J Wess and K A Jacobson
      Molecular Pharmacology September 1996, 50 (3) 512-521;

  7. Klaassen, C D

    1. Ontogeny and hormonal basis of male-dominant rat hepatic sulfotransferases.
      L Liu and C D Klaassen
      Molecular Pharmacology September 1996, 50 (3) 565-572;

  8. Knoll, B J

    1. Repetitive endocytosis and recycling of the beta 2-adrenergic receptor during agonist-induced steady state redistribution.
      K J Morrison, R H Moore, N D Carsrud, J Trial, E E Millman, M Tuvim, R B Clark, R Barber, B F Dickey and B J Knoll
      Molecular Pharmacology September 1996, 50 (3) 692-699;

  9. Kurose, K

    1. Okadaic acid potentiates 3-methylcholanthrene-induced CYP2A8 gene expression in primary cultures of Syrian hamster hepatocytes: possible involvement of activator protein-1.
      M Tohkin, K Kurose and M Fukuhara
      Molecular Pharmacology September 1996, 50 (3) 556-564;

L

  1. Lau, S S

    1. Quinone thioether-mediated DNA damage, growth arrest, and gadd153 expression in renal proximal tubular epithelial cells.
      J K Jeong, J L Stevens, S S Lau and T J Monks
      Molecular Pharmacology September 1996, 50 (3) 592-598;

  2. Lee, H C

    1. Cyclic AMP-dependent phosphodiesterase isozyme-specific potentiation by protein kinase C in hypertrophic cardiomyopathic hamster hearts.
      H Yu, J J Cai and H C Lee
      Molecular Pharmacology September 1996, 50 (3) 549-555;

  3. Lerner, M R

    1. Morphine down-regulates melanocortin-4 receptor expression in brain regions that mediate opiate addiction.
      J D Alvaro, J B Tatro, J M Quillan, M Fogliano, M Eisenhard, M R Lerner, E J Nestler and R S Duman
      Molecular Pharmacology September 1996, 50 (3) 583-591;

  4. Levi, P E

    1. Piperonyl butoxide and acenaphthylene induce cytochrome P450 1A2 and 1B1 mRNA in aromatic hydrocarbon-responsive receptor knock-out mouse liver.
      D Y Ryu, P E Levi, P Fernandez-Salguero, F J Gonzalez and E Hodgson
      Molecular Pharmacology September 1996, 50 (3) 443-446;

  5. Lheureux, F

    1. BIBW22 BS, potent multidrug resistance-reversing agent, binds directly to P-glycoprotein and accumulates in drug-resistant cells.
      Z Liu, F Lheureux, J F Pouliot, A Heckel, U Bamberger and E Georges
      Molecular Pharmacology September 1996, 50 (3) 482-492;

  6. Li, L Y

    1. The stimulatory effect of opioids on mitogen-activated protein kinase in Chinese hamster ovary cells transfected to express mu-opioid receptors.
      L Y Li and K J Chang
      Molecular Pharmacology September 1996, 50 (3) 599-602;

  7. Liliom, K

    1. N-palmitoyl-serine and N-palmitoyl-tyrosine phosphoric acids are selective competitive antagonists of the lysophosphatidic acid receptors.
      K Liliom, R Bittman, B Swords and G Tigyi
      Molecular Pharmacology September 1996, 50 (3) 616-623;

  8. Lindberg, R L

    1. Role of heme in cytochrome P450 transcription and function in mice treated with lead acetate.
      R Jover, R L Lindberg and U A Meyer
      Molecular Pharmacology September 1996, 50 (3) 474-481;

  9. Ling, N

    1. 125I-Tyro-sauvagine: a novel high affinity radioligand for the pharmacological and biochemical study of human corticotropin-releasing factor 2 alpha receptors.
      D E Grigoriadis, X J Liu, J Vaughn, S F Palmer, C D True, W W Vale, N Ling and E B De Souza
      Molecular Pharmacology September 1996, 50 (3) 679-686;

  10. Liu, L

    1. Ontogeny and hormonal basis of male-dominant rat hepatic sulfotransferases.
      L Liu and C D Klaassen
      Molecular Pharmacology September 1996, 50 (3) 565-572;

  11. Liu, X J

    1. 125I-Tyro-sauvagine: a novel high affinity radioligand for the pharmacological and biochemical study of human corticotropin-releasing factor 2 alpha receptors.
      D E Grigoriadis, X J Liu, J Vaughn, S F Palmer, C D True, W W Vale, N Ling and E B De Souza
      Molecular Pharmacology September 1996, 50 (3) 679-686;

  12. Liu, Z

    1. BIBW22 BS, potent multidrug resistance-reversing agent, binds directly to P-glycoprotein and accumulates in drug-resistant cells.
      Z Liu, F Lheureux, J F Pouliot, A Heckel, U Bamberger and E Georges
      Molecular Pharmacology September 1996, 50 (3) 482-492;

  13. Lobaugh, L A

    1. Constitutive activation of a phosphoinositidase C-linked G protein in murine fibroblasts decreases agonist-stimulated Ca2+ mobilization.
      L A Lobaugh, B Eisfelder, K Gibson, G L Johnson and J W Putney
      Molecular Pharmacology September 1996, 50 (3) 493-500;

  14. Lombardi, P

    1. Biochemical and pharmacological activity of novel 8-fluoroanthracyclines: influence of stereochemistry and conformation.
      F Animati, F Arcamone, M Bigioni, G Capranico, C Caserini, M De Cesare, P Lombardi, G Pratesi, C Salvatore, R Supino and F Zunino
      Molecular Pharmacology September 1996, 50 (3) 603-609;

M

  1. Macdonald, R L

    1. Pharmacological properties of gamma-aminobutyric acidA receptors from acutely dissociated rat dentate granule cells.
      J Kapur and R L Macdonald
      Molecular Pharmacology September 1996, 50 (3) 458-466;

  2. Mason, R P

    1. Detection of alpha-hydroxyethyl free radical adducts in the pancreas after chronic exposure to alcohol in the rat.
      Y Iimuro, B U Bradford, W Gao, M Kadiiska, R P Mason, B Stefanovic, D A Brenner and R G Thurman
      Molecular Pharmacology September 1996, 50 (3) 656-661;

  3. Matthes, H

    1. Functional selectivity of orphanin FQ for its receptor coexpressed with potassium channel subunits in Xenopus laevis oocytes.
      H Matthes, E P Seward, B Kieffer and R A North
      Molecular Pharmacology September 1996, 50 (3) 447-450;

  4. McDevitt, P

    1. Studies on alpha v beta 3/ligand interactions using a [3H]SK&F-107260 binding assay.
      A Wong, S M Hwang, P McDevitt, D McNulty, J M Stadel and K Johanson
      Molecular Pharmacology September 1996, 50 (3) 529-537;

  5. McEwan, I J

    1. Trans-activation by the human aryl hydrocarbon receptor and aryl hydrocarbon receptor nuclear translocator proteins: direct interactions with basal transcription factors.
      J C Rowlands, I J McEwan and J A Gustafsson
      Molecular Pharmacology September 1996, 50 (3) 538-548;

  6. McNulty, D

    1. Studies on alpha v beta 3/ligand interactions using a [3H]SK&F-107260 binding assay.
      A Wong, S M Hwang, P McDevitt, D McNulty, J M Stadel and K Johanson
      Molecular Pharmacology September 1996, 50 (3) 529-537;

  7. Meyer, U A

    1. Role of heme in cytochrome P450 transcription and function in mice treated with lead acetate.
      R Jover, R L Lindberg and U A Meyer
      Molecular Pharmacology September 1996, 50 (3) 474-481;

  8. Millman, E E

    1. Repetitive endocytosis and recycling of the beta 2-adrenergic receptor during agonist-induced steady state redistribution.
      K J Morrison, R H Moore, N D Carsrud, J Trial, E E Millman, M Tuvim, R B Clark, R Barber, B F Dickey and B J Knoll
      Molecular Pharmacology September 1996, 50 (3) 692-699;

  9. Molinoff, P B

    1. Use of subunit-specific antisense oligodeoxynucleotides to define developmental changes in the properties of N-methyl-D-aspartate receptors.
      J Zhong, V K Gribkoff and P B Molinoff
      Molecular Pharmacology September 1996, 50 (3) 631-638;

  10. Monks, T J

    1. Quinone thioether-mediated DNA damage, growth arrest, and gadd153 expression in renal proximal tubular epithelial cells.
      J K Jeong, J L Stevens, S S Lau and T J Monks
      Molecular Pharmacology September 1996, 50 (3) 592-598;

  11. Moore, R H

    1. Repetitive endocytosis and recycling of the beta 2-adrenergic receptor during agonist-induced steady state redistribution.
      K J Morrison, R H Moore, N D Carsrud, J Trial, E E Millman, M Tuvim, R B Clark, R Barber, B F Dickey and B J Knoll
      Molecular Pharmacology September 1996, 50 (3) 692-699;

  12. Moran, J L

    1. Induction of apoptosis by benzene metabolites in HL60 and CD34+ human bone marrow progenitor cells.
      J L Moran, D Siegel, X M Sun and D Ross
      Molecular Pharmacology September 1996, 50 (3) 610-615;

  13. Morrison, K J

    1. Repetitive endocytosis and recycling of the beta 2-adrenergic receptor during agonist-induced steady state redistribution.
      K J Morrison, R H Moore, N D Carsrud, J Trial, E E Millman, M Tuvim, R B Clark, R Barber, B F Dickey and B J Knoll
      Molecular Pharmacology September 1996, 50 (3) 692-699;

N

  1. Nestler, E J

    1. Morphine down-regulates melanocortin-4 receptor expression in brain regions that mediate opiate addiction.
      J D Alvaro, J B Tatro, J M Quillan, M Fogliano, M Eisenhard, M R Lerner, E J Nestler and R S Duman
      Molecular Pharmacology September 1996, 50 (3) 583-591;

  2. North, R A

    1. Functional selectivity of orphanin FQ for its receptor coexpressed with potassium channel subunits in Xenopus laevis oocytes.
      H Matthes, E P Seward, B Kieffer and R A North
      Molecular Pharmacology September 1996, 50 (3) 447-450;

  3. Nouet, S

    1. Agonist-induced modulation of inverse agonist efficacy at the beta 2-adrenergic receptor.
      P Chidiac, S Nouet and M Bouvier
      Molecular Pharmacology September 1996, 50 (3) 662-669;

O

  1. Ordentlich, A

    1. Interactions of oxime reactivators with diethylphosphoryl adducts of human acetylcholinesterase and its mutant derivatives.
      H Grosfeld, D Barak, A Ordentlich, B Velan and A Shafferman
      Molecular Pharmacology September 1996, 50 (3) 639-649;

P

  1. Palmer, S F

    1. 125I-Tyro-sauvagine: a novel high affinity radioligand for the pharmacological and biochemical study of human corticotropin-releasing factor 2 alpha receptors.
      D E Grigoriadis, X J Liu, J Vaughn, S F Palmer, C D True, W W Vale, N Ling and E B De Souza
      Molecular Pharmacology September 1996, 50 (3) 679-686;

  2. Pouliot, J F

    1. BIBW22 BS, potent multidrug resistance-reversing agent, binds directly to P-glycoprotein and accumulates in drug-resistant cells.
      Z Liu, F Lheureux, J F Pouliot, A Heckel, U Bamberger and E Georges
      Molecular Pharmacology September 1996, 50 (3) 482-492;

  3. Pratesi, G

    1. Biochemical and pharmacological activity of novel 8-fluoroanthracyclines: influence of stereochemistry and conformation.
      F Animati, F Arcamone, M Bigioni, G Capranico, C Caserini, M De Cesare, P Lombardi, G Pratesi, C Salvatore, R Supino and F Zunino
      Molecular Pharmacology September 1996, 50 (3) 603-609;

  4. Putney, J W

    1. Constitutive activation of a phosphoinositidase C-linked G protein in murine fibroblasts decreases agonist-stimulated Ca2+ mobilization.
      L A Lobaugh, B Eisfelder, K Gibson, G L Johnson and J W Putney
      Molecular Pharmacology September 1996, 50 (3) 493-500;

Q

  1. Quillan, J M

    1. Morphine down-regulates melanocortin-4 receptor expression in brain regions that mediate opiate addiction.
      J D Alvaro, J B Tatro, J M Quillan, M Fogliano, M Eisenhard, M R Lerner, E J Nestler and R S Duman
      Molecular Pharmacology September 1996, 50 (3) 583-591;

R

  1. Ross, D

    1. Induction of apoptosis by benzene metabolites in HL60 and CD34+ human bone marrow progenitor cells.
      J L Moran, D Siegel, X M Sun and D Ross
      Molecular Pharmacology September 1996, 50 (3) 610-615;

  2. Rowlands, J C

    1. Trans-activation by the human aryl hydrocarbon receptor and aryl hydrocarbon receptor nuclear translocator proteins: direct interactions with basal transcription factors.
      J C Rowlands, I J McEwan and J A Gustafsson
      Molecular Pharmacology September 1996, 50 (3) 538-548;

  3. Ryu, D Y

    1. Piperonyl butoxide and acenaphthylene induce cytochrome P450 1A2 and 1B1 mRNA in aromatic hydrocarbon-responsive receptor knock-out mouse liver.
      D Y Ryu, P E Levi, P Fernandez-Salguero, F J Gonzalez and E Hodgson
      Molecular Pharmacology September 1996, 50 (3) 443-446;

S

  1. Sadeghi, H

    1. A fully active nonglycosylated V2 vasopressin receptor.
      G Innamorati, H Sadeghi and M Birnbaumer
      Molecular Pharmacology September 1996, 50 (3) 467-473;

  2. Salvatore, C

    1. Biochemical and pharmacological activity of novel 8-fluoroanthracyclines: influence of stereochemistry and conformation.
      F Animati, F Arcamone, M Bigioni, G Capranico, C Caserini, M De Cesare, P Lombardi, G Pratesi, C Salvatore, R Supino and F Zunino
      Molecular Pharmacology September 1996, 50 (3) 603-609;

  3. Schmidt, R R

    1. Structural requirements of sphingosylphosphocholine and sphingosine-1-phosphate for stimulation of activator protein-1 activity.
      A Berger, R Bittman, R R Schmidt and S Spiegel
      Molecular Pharmacology September 1996, 50 (3) 451-457;

  4. Seward, E P

    1. Functional selectivity of orphanin FQ for its receptor coexpressed with potassium channel subunits in Xenopus laevis oocytes.
      H Matthes, E P Seward, B Kieffer and R A North
      Molecular Pharmacology September 1996, 50 (3) 447-450;

  5. Shafferman, A

    1. Interactions of oxime reactivators with diethylphosphoryl adducts of human acetylcholinesterase and its mutant derivatives.
      H Grosfeld, D Barak, A Ordentlich, B Velan and A Shafferman
      Molecular Pharmacology September 1996, 50 (3) 639-649;

  6. Shreeve, S M

    1. Direct evidence for functional coupling of the vasoactive intestinal peptide receptor to Gi3 in native lung membranes.
      N L Diehl, J C Kermode and S M Shreeve
      Molecular Pharmacology September 1996, 50 (3) 624-630;

  7. Siegel, D

    1. Induction of apoptosis by benzene metabolites in HL60 and CD34+ human bone marrow progenitor cells.
      J L Moran, D Siegel, X M Sun and D Ross
      Molecular Pharmacology September 1996, 50 (3) 610-615;

  8. Sikela, J

    1. Functional characterization of human gamma-aminobutyric acidA receptors containing the alpha 4 subunit.
      K A Wafford, S A Thompson, D Thomas, J Sikela, A S Wilcox and P J Whiting
      Molecular Pharmacology September 1996, 50 (3) 670-678;

  9. Sivertsen, S

    1. D-penicillamine causes free radical-dependent inactivation of activator protein-1 DNA binding.
      M L Handel, C K Watts, S Sivertsen, R O Day and R L Sutherland
      Molecular Pharmacology September 1996, 50 (3) 501-505;

  10. Spiegel, S

    1. Structural requirements of sphingosylphosphocholine and sphingosine-1-phosphate for stimulation of activator protein-1 activity.
      A Berger, R Bittman, R R Schmidt and S Spiegel
      Molecular Pharmacology September 1996, 50 (3) 451-457;

  11. Stadel, J M

    1. Studies on alpha v beta 3/ligand interactions using a [3H]SK&F-107260 binding assay.
      A Wong, S M Hwang, P McDevitt, D McNulty, J M Stadel and K Johanson
      Molecular Pharmacology September 1996, 50 (3) 529-537;

  12. Stefanovic, B

    1. Detection of alpha-hydroxyethyl free radical adducts in the pancreas after chronic exposure to alcohol in the rat.
      Y Iimuro, B U Bradford, W Gao, M Kadiiska, R P Mason, B Stefanovic, D A Brenner and R G Thurman
      Molecular Pharmacology September 1996, 50 (3) 656-661;

  13. Stevens, J L

    1. Quinone thioether-mediated DNA damage, growth arrest, and gadd153 expression in renal proximal tubular epithelial cells.
      J K Jeong, J L Stevens, S S Lau and T J Monks
      Molecular Pharmacology September 1996, 50 (3) 592-598;

  14. Sun, X M

    1. Induction of apoptosis by benzene metabolites in HL60 and CD34+ human bone marrow progenitor cells.
      J L Moran, D Siegel, X M Sun and D Ross
      Molecular Pharmacology September 1996, 50 (3) 610-615;

  15. Supino, R

    1. Biochemical and pharmacological activity of novel 8-fluoroanthracyclines: influence of stereochemistry and conformation.
      F Animati, F Arcamone, M Bigioni, G Capranico, C Caserini, M De Cesare, P Lombardi, G Pratesi, C Salvatore, R Supino and F Zunino
      Molecular Pharmacology September 1996, 50 (3) 603-609;

  16. Sutherland, R L

    1. D-penicillamine causes free radical-dependent inactivation of activator protein-1 DNA binding.
      M L Handel, C K Watts, S Sivertsen, R O Day and R L Sutherland
      Molecular Pharmacology September 1996, 50 (3) 501-505;

  17. Swords, B

    1. N-palmitoyl-serine and N-palmitoyl-tyrosine phosphoric acids are selective competitive antagonists of the lysophosphatidic acid receptors.
      K Liliom, R Bittman, B Swords and G Tigyi
      Molecular Pharmacology September 1996, 50 (3) 616-623;

T

  1. Tatro, J B

    1. Morphine down-regulates melanocortin-4 receptor expression in brain regions that mediate opiate addiction.
      J D Alvaro, J B Tatro, J M Quillan, M Fogliano, M Eisenhard, M R Lerner, E J Nestler and R S Duman
      Molecular Pharmacology September 1996, 50 (3) 583-591;

  2. Thomas, D

    1. Functional characterization of human gamma-aminobutyric acidA receptors containing the alpha 4 subunit.
      K A Wafford, S A Thompson, D Thomas, J Sikela, A S Wilcox and P J Whiting
      Molecular Pharmacology September 1996, 50 (3) 670-678;

  3. Thompson, S A

    1. Functional characterization of human gamma-aminobutyric acidA receptors containing the alpha 4 subunit.
      K A Wafford, S A Thompson, D Thomas, J Sikela, A S Wilcox and P J Whiting
      Molecular Pharmacology September 1996, 50 (3) 670-678;

  4. Thurman, R G

    1. Detection of alpha-hydroxyethyl free radical adducts in the pancreas after chronic exposure to alcohol in the rat.
      Y Iimuro, B U Bradford, W Gao, M Kadiiska, R P Mason, B Stefanovic, D A Brenner and R G Thurman
      Molecular Pharmacology September 1996, 50 (3) 656-661;

  5. Tigyi, G

    1. N-palmitoyl-serine and N-palmitoyl-tyrosine phosphoric acids are selective competitive antagonists of the lysophosphatidic acid receptors.
      K Liliom, R Bittman, B Swords and G Tigyi
      Molecular Pharmacology September 1996, 50 (3) 616-623;

  6. Tohkin, M

    1. Okadaic acid potentiates 3-methylcholanthrene-induced CYP2A8 gene expression in primary cultures of Syrian hamster hepatocytes: possible involvement of activator protein-1.
      M Tohkin, K Kurose and M Fukuhara
      Molecular Pharmacology September 1996, 50 (3) 556-564;

  7. Trial, J

    1. Repetitive endocytosis and recycling of the beta 2-adrenergic receptor during agonist-induced steady state redistribution.
      K J Morrison, R H Moore, N D Carsrud, J Trial, E E Millman, M Tuvim, R B Clark, R Barber, B F Dickey and B J Knoll
      Molecular Pharmacology September 1996, 50 (3) 692-699;

  8. True, C D

    1. 125I-Tyro-sauvagine: a novel high affinity radioligand for the pharmacological and biochemical study of human corticotropin-releasing factor 2 alpha receptors.
      D E Grigoriadis, X J Liu, J Vaughn, S F Palmer, C D True, W W Vale, N Ling and E B De Souza
      Molecular Pharmacology September 1996, 50 (3) 679-686;

  9. Tuvim, M

    1. Repetitive endocytosis and recycling of the beta 2-adrenergic receptor during agonist-induced steady state redistribution.
      K J Morrison, R H Moore, N D Carsrud, J Trial, E E Millman, M Tuvim, R B Clark, R Barber, B F Dickey and B J Knoll
      Molecular Pharmacology September 1996, 50 (3) 692-699;

V

  1. Vale, W W

    1. 125I-Tyro-sauvagine: a novel high affinity radioligand for the pharmacological and biochemical study of human corticotropin-releasing factor 2 alpha receptors.
      D E Grigoriadis, X J Liu, J Vaughn, S F Palmer, C D True, W W Vale, N Ling and E B De Souza
      Molecular Pharmacology September 1996, 50 (3) 679-686;

  2. Van Rhee, A M

    1. Hydrophilic side chains in the third and seventh transmembrane helical domains of human A2A adenosine receptors are required for ligand recognition.
      Q Jiang, A M Van Rhee, J Kim, S Yehle, J Wess and K A Jacobson
      Molecular Pharmacology September 1996, 50 (3) 512-521;

  3. Vaughn, J

    1. 125I-Tyro-sauvagine: a novel high affinity radioligand for the pharmacological and biochemical study of human corticotropin-releasing factor 2 alpha receptors.
      D E Grigoriadis, X J Liu, J Vaughn, S F Palmer, C D True, W W Vale, N Ling and E B De Souza
      Molecular Pharmacology September 1996, 50 (3) 679-686;

  4. Velan, B

    1. Interactions of oxime reactivators with diethylphosphoryl adducts of human acetylcholinesterase and its mutant derivatives.
      H Grosfeld, D Barak, A Ordentlich, B Velan and A Shafferman
      Molecular Pharmacology September 1996, 50 (3) 639-649;

W

  1. Wafford, K A

    1. Functional characterization of human gamma-aminobutyric acidA receptors containing the alpha 4 subunit.
      K A Wafford, S A Thompson, D Thomas, J Sikela, A S Wilcox and P J Whiting
      Molecular Pharmacology September 1996, 50 (3) 670-678;

  2. Wang, X

    1. Mercury binding site on Na+/K(+)-ATPase: a cysteine in the first transmembrane segment.
      X Wang and J D Horisberger
      Molecular Pharmacology September 1996, 50 (3) 687-691;

  3. Watts, C K

    1. D-penicillamine causes free radical-dependent inactivation of activator protein-1 DNA binding.
      M L Handel, C K Watts, S Sivertsen, R O Day and R L Sutherland
      Molecular Pharmacology September 1996, 50 (3) 501-505;

  4. Wess, J

    1. Hydrophilic side chains in the third and seventh transmembrane helical domains of human A2A adenosine receptors are required for ligand recognition.
      Q Jiang, A M Van Rhee, J Kim, S Yehle, J Wess and K A Jacobson
      Molecular Pharmacology September 1996, 50 (3) 512-521;

  5. Whiting, P J

    1. Functional characterization of human gamma-aminobutyric acidA receptors containing the alpha 4 subunit.
      K A Wafford, S A Thompson, D Thomas, J Sikela, A S Wilcox and P J Whiting
      Molecular Pharmacology September 1996, 50 (3) 670-678;

  6. Wilcox, A S

    1. Functional characterization of human gamma-aminobutyric acidA receptors containing the alpha 4 subunit.
      K A Wafford, S A Thompson, D Thomas, J Sikela, A S Wilcox and P J Whiting
      Molecular Pharmacology September 1996, 50 (3) 670-678;

  7. Wong, A

    1. Studies on alpha v beta 3/ligand interactions using a [3H]SK&F-107260 binding assay.
      A Wong, S M Hwang, P McDevitt, D McNulty, J M Stadel and K Johanson
      Molecular Pharmacology September 1996, 50 (3) 529-537;

Y

  1. Yehle, S

    1. Hydrophilic side chains in the third and seventh transmembrane helical domains of human A2A adenosine receptors are required for ligand recognition.
      Q Jiang, A M Van Rhee, J Kim, S Yehle, J Wess and K A Jacobson
      Molecular Pharmacology September 1996, 50 (3) 512-521;

  2. Yu, H

    1. Cyclic AMP-dependent phosphodiesterase isozyme-specific potentiation by protein kinase C in hypertrophic cardiomyopathic hamster hearts.
      H Yu, J J Cai and H C Lee
      Molecular Pharmacology September 1996, 50 (3) 549-555;

Z

  1. Zhong, J

    1. Use of subunit-specific antisense oligodeoxynucleotides to define developmental changes in the properties of N-methyl-D-aspartate receptors.
      J Zhong, V K Gribkoff and P B Molinoff
      Molecular Pharmacology September 1996, 50 (3) 631-638;

  2. Zhu, D

    1. Calcineurin mutants render T lymphocytes resistant to cyclosporin A.
      D Zhu, M E Cardenas and J Heitman
      Molecular Pharmacology September 1996, 50 (3) 506-511;

  3. Zunino, F

    1. Biochemical and pharmacological activity of novel 8-fluoroanthracyclines: influence of stereochemistry and conformation.
      F Animati, F Arcamone, M Bigioni, G Capranico, C Caserini, M De Cesare, P Lombardi, G Pratesi, C Salvatore, R Supino and F Zunino
      Molecular Pharmacology September 1996, 50 (3) 603-609;
Back to top

In this issue

Advertisement